A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

Exclusion Criteria

• •has received HPV vaccine previously; have received other research or unregistered product (drug or vaccine) within 30 days before the first injection
• •within three months before the first injection, has had received a whole-blood, plasma or immunoglobulin treatment, or planed to receive such treatments during the research period; within 28 days before the research, has had received attenuated live vaccine; or within 14 days has had received inactivated vaccine
• •has a history of allergic reaction which requires medical intervention; has allergic reaction for vaccine or vaccine-containing elements; has serious adverse effect history for vaccine
• •has a history of epilepsy, convulsion or has a family history of mental diseases
• •has immunodeficiency diseases including: AIDS, HIV infection, lymphoma, leukemia, Systemic Lupus Erythematosus, rheumatoid arthritis, Juvenile Rheumatoid Arthritis, inflammatory bowel disease
• •used immunosuppressor for treatment or corticosteroid drugs for systemic medication in 6 months
• •asplenia, functional asplenia, or splenectomize
• •liver and kidney diseases, serious cardiovascular diseases, diabetes, history of malignant tumor
• •coagulation disorders
• •in menstrual period or acute diseases
• •pregnant, or less than 8 weeks after delivery
• •has a history of sexual transmitted disease
• •had total hysterectomy or pelvic radiotherapy
• •has cervical abnormalities
• •abnormal screening results for cervical cancer or had CIN in two years
• •according to the judgement of investigator, participant has conditions that were not suitable for this trial
• •planning to move out of the clinical trial site during the research period
• •never has vaginal sexual activity